Why Amgen Stock Was Crushing It on Wednesday

Group 1 - Amgen's stock rose over 8% following the release of its third-quarter results, indicating strong investor confidence [1] - The company reported a 12% year-over-year increase in total revenue, reaching $9.6 billion, driven by significant sales growth of key drugs [2] - Non-GAAP net income increased by 1% to just under $3.06 billion, or $5.64 per share, surpassing analyst expectations [2][3] Group 2 - Amgen attributed its better-than-expected performance to volume growth and emphasized its focus on expanding access and innovation for long-term growth [4] - The company raised its full-year 2025 revenue guidance to a range of $35.8 billion to $36.6 billion, up from the previous range of $35 billion to $36 billion [5] - Adjusted net income forecast was also increased to $20.60 to $21.40 per share, compared to the prior forecast of $20.20 to $21.30 [5]